Evidence map›Paper›PMID 39582293›Full record

ArticleBiomarkers in medicine2024

N-glycan as new potential biomarker for predicting treatment response in patients with type 2 diabetes mellitus.

Hui-Jun Dong, Xiao-Hui Li, Qi-Xin Gu, Chi-Fa Ma, Ming-Xia Yuan, Zhen-Zi Wang, Jian-Rong Su, Lei Xu, Cui-Ying Chen, Qiqige Ebule and 2 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarkers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Hui-Jun DongDepartment of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Xiao-Hui LiDepartment of Endocrinology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Qi-Xin GuDepartment of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Chi-Fa MaDepartment of Endocrinology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ming-Xia YuanDepartment of Endocrinology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Zhen-Zi WangDepartment of laboratory medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jian-Rong SuDepartment of laboratory medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Lei XuDepartment of Research and Development, Sysdiagno (Nanjing) Biotech Co., Ltd, Nanjing, Jiangsu Province, China.
Cui-Ying ChenDepartment of Research and Development, Sysdiagno (Nanjing) Biotech Co., Ltd, Nanjing, Jiangsu Province, China.
Qiqige EbuleDepartment of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Hui ZhuangDepartment of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Xue-En LiuDepartment of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate the N-glycans related to the metformin efficacy in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND

methodsWe enrolled 141 healthy controls and 195 newly diagnosed T2DM patients treated with metformin for 3 months. Serum N-glycan profile was determined by DNA sequencer - assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE). The N-glycan model was established by logistic regression analysis. Receiver operating characteristic curve (ROC) analysis was used to analyze the predictive power of the N-glycan model for metformin efficacy.

resultsThe abundances of several N-glycans in serum of T2DM patients at baseline were significantly different from those of healthy controls and tended to recover the N-glycan of controls after 3 months treatment. Serum N-glycans changes were more significant in the good response group (FPG <7 mmol/L) after metformin treatment. In addition, the abundance of peak9 at baseline had an opposite tendency between HbA1c increased and decreased groups post-treatment, which could be a biomarker for predicting metformin efficacy. Peak9 combined with other 11 N-glycans at baseline was used to establish the predictive model to distinguish non-response from response patients (AUROC = 0.780, sensitivity = 70.6% and specificity = 77.5%).

conclusionsSerum N-glycans may have potential value as biomarkers for indicating the efficacy of metformin.

Indexed as

BiomarkersDiabetes Mellitus, Type 2MetforminPolysaccharidesAdultAgedCase-Control StudiesFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMiddle AgedROC CurveTreatment OutcomeBiomarkersGlycated HemoglobinHypoglycemic AgentsMetforminPolysaccharidesclinical indicatorsmetforminN-glycan biomarkertreatment responsetype 2 diabetes mellitus

Identifiers

PMID39582293
PMCPMC11654830

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.